Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients
Mathias Rummel(Universitätsklinikum Gießen und Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Martina Stauch, M. Baldus, Ulrich von Gruenhagen(Praxis für Hämatologie und Onkologie), H. Bodenstein(Pius Hospital Oldenburg), A. Banat(Justus-Liebig-Universität Gießen), K. Heine
Cited by 15
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
|Blood|2010|485
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425